Bursting cancer’s bubble:
High-potency oncolytic viruses for
high-impact cancer therapy
The promise of
oncolytic virus (OV)
For centuries, there have been isolated reports of tumor regression in cancer patients during the course of naturally acquired viral infections. However, these responses were partial and transient. The OV therapeutic class seeks to harness the anti-neoplastic potential of naturally occurring viruses, and enhance potency, durability of response, and safety through synthetic engineering.
At IconOVir, we are dedicated to the development of potent, tumor-selective, systemically available oncolytic Adenoviruses for the treatment of a broad range of solid tumors. Drawing on our deep understanding of adenoviral biology and leveraging extensive proprietary capabilities in high-throughput viral engineering and characterization, we seek to deliver on the full potential of the oncolytic virus modality.
How do oncolytic viruses work?
OVs drive anti-cancer response
through rapid tumor killing followed
by potent immune response
Virus-Mediated Tumor Killing
Exponential lytic replications seeds tumor environment with cytokines and neoantigen-containing cell debris
Potent Immune Response
Innate and adaptive immunity prime a systemic and durable anti-tumor response
IconOVir’s synthetic virology platform:
At IconOVir, we leverage high-throughput synthetic and systems biology capabilities for rapid iterative design and optimization of next-generation OVs
Iterative Rational Design, Rapid Assembly and Testing